USANA HEALTH SCIENCES INC
For the period ended Dec 28, 2024. Filed Mar 12, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 12, 2025
USNA$13.10-5.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Year Ended | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Cash flows from operating activities | |||
| Net earnings | $42,060 | $63,788 | $69,350 |
| Adjustments to reconcile net earnings to net cash provided by (used in) operating activities | |||
| Depreciation and amortization | 14,539 | 12,702 | 13,393 |
| Right-of-use asset reduction | 7,690 | 7,693 | 8,017 |
| (Gain) loss on sale of property and equipment | 1 | 10 | 141 |
| Equity-based compensation expense | 14,558 | 14,595 | 13,331 |
| Deferred income taxes | (6,744) | (2,749) | (7,183) |
| Inventory write-down | 1,891 | 2,601 | 6,082 |
| Changes in operating assets and liabilities, net of acquisitions: | |||
| Inventories | (2,118) | 2,353 | 15,797 |
| Prepaid expenses and other assets | (2,871) | 110 | (3,304) |
| Accounts payable | (1,269) | (428) | (2,656) |
| Other liabilities | (6,745) | (30,034) | (9,066) |
| Net cash provided by (used in) operating activities | 60,992 | 70,641 | 103,902 |
| Cash flows from investing activities | |||
| Proceeds from the settlement of net investment hedges | 1,125 | 3,775 | 4,555 |
| Payments for net investment hedge | (870) | (1,271) | — |
| Payments to acquire businesses, net of cash acquired | (203,336) | — | (6,532) |
| Proceeds from sale of property and equipment | 64 | 15 | 7 |
| Purchases of property and equipment | (10,073) | (14,494) | (10,400) |
| Net cash provided by (used in) investing activities | (213,090) | (11,975) | (12,370) |
| Cash flows from financing activities | |||
| Repurchase of common stock | (9,444) | (11,599) | (25,382) |
| Borrowings on line of credit | 23,687 | 1,542 | 11,000 |
| Payments on line of credit | (1,467) | (750) | (11,000) |
| Payments related to tax withholding for net-share settled equity awards | (3,223) | (3,092) | (4,706) |
| Payments for contingent consideration | — | (338) | — |
| Net cash provided by (used in) financing activities | 9,553 | (14,237) | (30,088) |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | (6,193) | (2,503) | (13,777) |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | (148,738) | 41,926 | 47,667 |
| Cash, cash equivalents, and restricted cash at beginning of period | 333,246 | 291,320 | 243,653 |
| Cash, cash equivalents, and restricted cash at end of period | $184,508 | $333,246 | $291,320 |
CONSOLIDATED STATEMENTS OF CASH FLOWS - CONTINUED
| Year Ended | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets | |||
| Cash and cash equivalents | $181,768 | $330,420 | $288,420 |
| Restricted cash included in other assets | 2,740 | 2,826 | 2,900 |
| Total cash, cash equivalents, and restricted cash | $184,508 | $333,246 | $291,320 |
| Supplemental disclosures of cash flow information | |||
| Cash paid during the period for: | |||
| Interest | $76 | $68 | $49 |
| Income taxes | 40,470 | 44,247 | 45,863 |
| Cash received during the period for: | |||
| Income tax refund | 75 | 1,922 | 113 |
| Non-cash investing and financing activities: | |||
| Right-of-use assets obtained in exchange for lease obligations | 12,463 | 5,699 | 5,641 |
| Net working capital adjustment receivable | 778 | — | — |
| Accrued purchases of property and equipment | 42 | 117 | 679 |
| Contingent consideration given to acquire businesses | — | — | 886 |
| Accrued excise tax for repurchase of common stock | 39 | 54 | — |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.